An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

Overview of attention for article published in OncoImmunology, October 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,596 followers.

RT @BONUSOncSoc: Come along to UoB OncSoc's Journal Club at 6pm tonight! Topic: Immunotherapy (For Melanoma) Full paper link: https://t.c…

Come along to UoB OncSoc's Journal Club at 6pm tonight! Topic: Immunotherapy (For Melanoma) Full paper link: https://t.co/sbXhwTDZJT Sign-up Link: https://t.co/s2TwdglVTv Zoom link: https://t.co/dcYC8w51bw https://t.co/Li9kproIK1

New article: An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma https://t.co/39lc688BJ1 #melanoma #oncology https://t.co/TVH2NBtof0

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.